Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM | Research To Practice
British Journal of Haematology | Wiley Online Library
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
DREAMM Clinical Trial Program
Overall survival in patients receiving bortezomib or dexamethasone with... | Download Scientific Diagram
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
Changes in hemoglobin and IgA levels. BDR: bortezomib, dexamethasone,... | Download Scientific Diagram
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis - Biology of Blood and Marrow Transplantation
British Journal of Haematology | Wiley Online Library
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
![PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2f0ca3b1a7ecfca0a8a6fce95c955879f5ec3e35/9-Table3-1.png "PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar")
PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
BOSTON trial (SVd) Update at ASCO 2020 | Int Myeloma Fn
Cancers | Free Full-Text | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
British Journal of Haematology | Wiley Online Library
